Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization (Cancer Chemotherapy and Pharmacology, (2017), 80, 6, (1171-1178), 10.1007/s00280-017-3463-x)

DSpace/Manakin Repository

Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization (Cancer Chemotherapy and Pharmacology, (2017), 80, 6, (1171-1178), 10.1007/s00280-017-3463-x)
 
Verheijen, R B; Swart, E L; Beijnen, J H; Schellens, J H M; Huitema, A D R; Steeghs, N
(2020) Cancer Chemotherapy and Pharmacology, volume 86, issue 1, pp.
(Comment)
Abstract
In the original publication of the article, the second author name has been misspelled.
Download/Full Text
The full text of this publication is not available.
Version on publisher website for UU-students and staff
Version on publisher website
 
Keywords: Pharmacology (medical), Oncology, Cancer Research, Toxicology, Pharmacology, Published Erratum
DOI: https://doi.org/10.1007/s00280-020-04090-4
ISSN: 0344-5704
Publisher: Springer-Verlag
Note: Publisher Copyright: © 2020, Springer-Verlag GmbH Germany, part of Springer Nature. Copyright: Copyright 2020 Elsevier B.V., All rights reserved.
(Peer reviewed)